Literature DB >> 28514998

Affibody Molecules in Biotechnological and Medical Applications.

Stefan Ståhl1, Torbjörn Gräslund2, Amelie Eriksson Karlström2, Fredrik Y Frejd3, Per-Åke Nygren2, John Löfblom2.   

Abstract

Affibody molecules are small (6.5-kDa) affinity proteins based on a three-helix bundle domain framework. Since their introduction 20 years ago as an alternative to antibodies for biotechnological applications, the first therapeutic affibody molecules have now entered clinical development and more than 400 studies have been published in which affibody molecules have been developed and used in a variety of contexts. In this review, we focus primarily on efforts over the past 5 years to explore the potential of affibody molecules for medical applications in oncology, neurodegenerative, and inflammation disorders, including molecular imaging, receptor signal blocking, and delivery of toxic payloads. In addition, we describe recent examples of biotechnological applications, in which affibody molecules have been exploited as modular affinity fusion partners.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  affibody; affinity protein; alternative scaffolds; biologicals; molecular imaging; next-generation biotherapeutics; targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 28514998     DOI: 10.1016/j.tibtech.2017.04.007

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  83 in total

Review 1.  Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.

Authors:  Ghazal Nabil; Ketki Bhise; Samaresh Sau; Mohamed Atef; Hossny A El-Banna; Arun K Iyer
Journal:  Drug Discov Today       Date:  2018-08-16       Impact factor: 7.851

2.  Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.

Authors:  Junpeng Qi; Xiuling Li; Haiyong Peng; Erika M Cook; Eman L Dadashian; Adrian Wiestner; HaJeung Park; Christoph Rader
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

Review 3.  Aligning physics and physiology: Engineering antibodies for radionuclide delivery.

Authors:  Wen-Ting K Tsai; Anna M Wu
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-15       Impact factor: 1.921

Review 4.  The variable lymphocyte receptor as an antibody alternative.

Authors:  Elizabeth A Waters; Eric V Shusta
Journal:  Curr Opin Biotechnol       Date:  2018-03-26       Impact factor: 9.740

5.  Reactive oxygen species and enzyme dual-responsive biocompatible drug delivery system for targeted tumor therapy.

Authors:  Ning Zhao; Bingbing Ding; Ying Zhang; Jessica L Klockow; Ken Lau; Frederick T Chin; Zhen Cheng; Hongguang Liu
Journal:  J Control Release       Date:  2020-05-23       Impact factor: 9.776

6.  PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.

Authors:  Shibo Qi; Susan Hoppmann; Yingding Xu; Zhen Cheng
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

7.  Affibody-Indocyanine Green Based Contrast Agent for Photoacoustic and Fluorescence Molecular Imaging of B7-H3 Expression in Breast Cancer.

Authors:  Rakesh Bam; Makenna Laffey; Katharine Nottberg; Patrick S Lown; Benjamin J Hackel; Katheryne E Wilson
Journal:  Bioconjug Chem       Date:  2019-05-24       Impact factor: 4.774

8.  Site-Specific Labeling of F-18 Proteins Using a Supplemented Cell-Free Protein Synthesis System and O-2-[18F]Fluoroethyl-L-Tyrosine: [18F]FET-HER2 Affibody Molecule.

Authors:  Ai Yanai; Ryuichi Harada; Ren Iwata; Takeo Yoshikawa; Yoichi Ishikawa; Shozo Furumoto; Takanori Ishida; Kazuhiko Yanai
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

9.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

10.  Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle.

Authors:  Chao Zhang; Mengnan Han; Fanghua Zhang; Xueli Yang; Jie Du; Honglei Zhang; Wei Li; Shengxi Chen
Journal:  Int J Nanomedicine       Date:  2020-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.